Thoughts on transatlantic regulatory cooperation in pharmaceuticals after: #TTIPleaks

Research output: Contribution to journalArticlepeer-review


The leak of confidential documents on 2 May 2016 by GreenpeaceNetherlands allows some preliminary conclusions on both the scope and success of the negotiations so far. As regards the pharmaceuticalmarket, the current state of affairs combines the promise of steps forward with the prospect of concerning standstills. This short opinion follows key points emerging from the leaked documents n.9 (“RegulatoryCooperation”) andn.16 (“TacticalState ofPlay”) that are directly relevant to the pharmaceutical market. The themes that will be briefly discussed are, first, the regulatory cooperation mechanisms emerging fromdoc. n.9 in comparison to current cooperation processes in pharmaceutical regulation. The leaked papers suggest positive and commendable (yet far from conclusive) developments towards amore transparent and regulated framework for cooperation, while perpetuating concerns regarding fundamental policy choices and prevalence ofmercantile imperatives over competing public interests.
Original languageEnglish
Pages (from-to)280-284
Number of pages5
JournalEuropean Journal of Risk Regulation
Issue number2
Publication statusPublished - 2016
Externally publishedYes


Dive into the research topics of 'Thoughts on transatlantic regulatory cooperation in pharmaceuticals after: #TTIPleaks'. Together they form a unique fingerprint.

Cite this